Comparison of clinical efficacy between twice-daily formoterol/budesonide combinations and once-daily fluticasone furoate/vilanterol in bronchial asthma

Trial Profile

Comparison of clinical efficacy between twice-daily formoterol/budesonide combinations and once-daily fluticasone furoate/vilanterol in bronchial asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Vilanterol/fluticasone furoate (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jul 2017 Status changed from recruiting to completed as per the results presented at the 113th International Conference of the American Thoracic Society
    • 24 May 2017 Primary endpoint (Change from baseline (0 week) in FEV1 after 8 weeks of treatment, once-daily FF/VI versus twice-daily budesonide (BUD) / formoterol) has not been met as per the results presented at the 113th International Conference of the American Thoracic Society
    • 24 May 2017 Results (n=21) presented at the 113th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top